Healthcare: Biogen's Alzheimer's Drug Goes From Bust To Boon, Plus Why Walgreen's Shuttering 200 Healthcare Clinics
Biogen's drug pipeline took a massive hit earlier this year when it stopped development of its Alzheimer's disease drug, aducanumab, for a lack of efficacy. Now, Biogen says new data shows it may work after all. Can this drug pass muster with regulators? Also, Walgreen's is closing retail clinics within its stores, but that doesn't mean it's giving up on plans to offer more healthcare services entirely. Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter To get 50% off our Stock Advisor service, go to http://IF.Fool.com.